Helicobacter Pylori Eradication Study in Parkinson's Disease
Status:
Completed
Trial end date:
2016-05-01
Target enrollment:
Participant gender:
Summary
It has been hypothesized, based on epidemiological observations, that Helicobacter pylori
(HP) infection may play a role in the pathogenesis of Parkinson's Disease (PD). Previous
studies have also shown that HP eradication therapy may result in improvements in levodopa
pharmacokinetics and motor fluctuations. This study aims to examine the effects of HP
eradication, using a double-blind randomized placebo-controlled trial design in a relatively
large cohort of patients. Outcomes of interest include motor function, gastrointestinal
symptoms and health-related quality of life. The investigators hypothesize that HP
eradication will lead to improvements in motor function. The primary outcome of interest is
the "ON"-medication Unified PD Rating Scale (UPDRS) Part III score at 3 months. Secondary
outcomes include Purdue Pegboard Score, Timed Test of Gait, Dyskinesia and Bradykinesia
scores measured by Parkinson's Kinetigraph (PKG), Leeds Dyspepsia Questionnaire (LDQ),
Parkinson's Disease Questionnaire (PDQ-39), UPDRS Part I, Part II and Part IV; and Montreal
Cognitive Assessment (MOCA).